FDA Approves Nemolizumab for Prurigo Nodularis
Breakthrough Treatment for Chronic Skin Condition
The US Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio) as a pre-filled pen for subcutaneous administration for the treatment of adults with prurigo nodularis (PN), a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin.
Promising Results in Phase III Trials
The FDA's approval is based on positive results from a Phase III double-blind, multicenter, randomized trial involving adults with moderate-to-severe prurigo nodularis. In the study, participants receiving nemolizumab experienced significant improvements in itch severity and skin lesions compared to those given a placebo.
Comments